- Home
- PVH vs NUVL Comparison
PVH vs NUVL Comparison
Compare PVH & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVH
- NUVL
- Stock Information
- Founded
- PVH 1881
- NUVL 2017
- Country
- PVH United States
- NUVL United States
- Employees
- PVH N/A
- NUVL N/A
- Industry
- PVH Apparel
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- PVH Consumer Discretionary
- NUVL Health Care
- Exchange
- PVH Nasdaq
- NUVL Nasdaq
- Market Cap
- PVH 6.1B
- NUVL 5.6B
- IPO Year
- PVH N/A
- NUVL 2021
- Fundamental
- Price
- PVH $74.48
- NUVL $69.85
- Analyst Decision
- PVH Buy
- NUVL Strong Buy
- Analyst Count
- PVH 15
- NUVL 8
- Target Price
- PVH $103.00
- NUVL $115.50
- AVG Volume (30 Days)
- PVH 1.0M
- NUVL 636.2K
- Earning Date
- PVH 06-03-2025
- NUVL 05-08-2025
- Dividend Yield
- PVH 0.20%
- NUVL N/A
- EPS Growth
- PVH N/A
- NUVL N/A
- EPS
- PVH 10.56
- NUVL N/A
- Revenue
- PVH $8,652,900,000.00
- NUVL N/A
- Revenue This Year
- PVH $1.11
- NUVL N/A
- Revenue Next Year
- PVH $2.25
- NUVL N/A
- P/E Ratio
- PVH $7.05
- NUVL N/A
- Revenue Growth
- PVH N/A
- NUVL N/A
- 52 Week Low
- PVH $59.28
- NUVL $55.54
- 52 Week High
- PVH $124.68
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- PVH 57.53
- NUVL 46.22
- Support Level
- PVH $66.84
- NUVL $63.56
- Resistance Level
- PVH $76.81
- NUVL $78.97
- Average True Range (ATR)
- PVH 2.42
- NUVL 3.46
- MACD
- PVH 0.49
- NUVL -0.38
- Stochastic Oscillator
- PVH 76.63
- NUVL 40.84
About PVH PVH Corp.
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites and about 1,500 stores, licenses its brands to third parties, and distributes its merchandise through department stores and other wholesale accounts. The firm traces its history to 1881 and is based in New York City.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.